利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

109 条记录 (耗时 0.027 秒)

    Methods of treatment involving the protease for activating clotting factor VII
    51.
    发明授权
    Methods of treatment involving the protease for activating clotting factor VII 有权
    涉及蛋白酶激活凝血因子VII的治疗方法

    公开(公告)号：US07879803B2

    公开(公告)日：2011-02-01

    申请号：US11984058

    申请日：2007-11-13

    申请人： Jürgen Römisch ,  Annette Feussner ,  Hans-Arnold Stöhr

    发明人： Jürgen Römisch ,  Annette Feussner ,  Hans-Arnold Stöhr

    IPC分类号： A61K38/00

    CPC分类号： A61L15/38 ,  A61K38/00 ,  A61K38/57 ,  C07K14/745 ,  C12N9/6424 ,  C12Q1/56 ,  G01N33/86 ,  G01N2333/96447

    摘要： This application describes methods of treatment involving a protease for activating the blood clotting factor VII, which (a) activates blood clotting factor VII, (b) is inhibited by the presence of aprotinin, (c) is increased in its activity by the presence of at least one of the following: calcium ions, heparin, or heparin related substances, and (d) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more bands in the molecular weight range from 50 to 75 kDa, and in the reduced state has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa, and a band, which corresponds to a proenzyme, in the molecular weight range from 60 to 65 kDa.

    摘要翻译： 本申请描述了涉及用于激活血液凝固因子VII的蛋白酶的治疗方法，其中（a）激活血液凝固因子VII，（b）被抑肽酶抑制，（c）通过存在抑制素而增加其活性 以下中的至少一种：钙离子，肝素或肝素相关物质，和（d）在SDS-PAGE中，在未还原状态下随后的染色具有一个或多个分子量范围为50至75的条带 kDa，并且在还原状态下具有40至55kDa的条带和分子量范围为10至35kDa的一个或多个条带和对应于分子量范围为60至65的酶的条带 kDa。

    Modified Vitamin K Dependent Polypeptides
    52.
    发明申请
    Modified Vitamin K Dependent Polypeptides 有权
    修饰维生素K依赖性多肽

    公开(公告)号：US20090130060A1

    公开(公告)日：2009-05-21

    申请号：US11632552

    申请日：2005-08-10

    申请人： Thomas Weimer ,  Stefan Schulte ,  Kay Hofmann ,  Hans-Peter Hauser

    发明人： Thomas Weimer ,  Stefan Schulte ,  Kay Hofmann ,  Hans-Peter Hauser

    IPC分类号： A61K35/74 ,  C07K1/00 ,  C07K14/00 ,  C12N9/50 ,  C12N15/11 ,  C12N15/00 ,  C12N1/21 ,  C12P21/04 ,  A61K38/16 ,  A61K31/7088

    CPC分类号： C12N15/62 ,  C12N9/6424

    摘要： The present invention relates to modified cDNA sequences coding for vitamin K-dependent polypeptides, in particular human Factor VII, human Factor VIIa, human Factor IX and human protein C and their derivatives with improved stability and extended plasma half life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.

    摘要翻译： 本发明涉及编码维生素K依赖多肽，特别是人因子VII，人因子VIIa，人因子IX和人蛋白C及其衍生物的修饰cDNA序列，其具有改善的稳定性和延长的血浆半衰期，含有这样的重组表达载体 cDNA序列，用这种重组表达载体转化的宿主细胞，确实具有未修饰的野生型蛋白质的生物活性但具有改进的稳定性的生物活性的重组多肽和衍生物，以及制备这些重组蛋白及其衍生物的方法。 本发明还涵盖用于人基因治疗的转移载体，其包含这种修饰的DNA序列。

    Hydrophobic charge induction chromatographic depletion of a protein from a solution
    56.
    发明授权
    Hydrophobic charge induction chromatographic depletion of a protein from a solution 有权

    公开(公告)号：US10188965B2

    公开(公告)日：2019-01-29

    申请号：US14649374

    申请日：2013-12-05

    申请人： CSL LIMITED

    发明人： Hung Pham ,  Jeffrey Michael Hey ,  Darren Nguy

    IPC分类号： C07K14/75 ,  B01D15/36 ,  A61J1/05 ,  C07K14/745 ,  C07K14/755 ,  A61K38/00

    摘要： The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in the solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof.

    Holder for an injection syringe
    60.
    发明授权
    Holder for an injection syringe 有权
    注射器的支架

    公开(公告)号：US09474851B2

    公开(公告)日：2016-10-25

    申请号：US13704019

    申请日：2011-06-15

    申请人： Dieter Plünnecke

    发明人： Dieter Plünnecke

    IPC分类号： A61M5/00 ,  A61M5/31

    CPC分类号： A61M5/008 ,  A61M2005/3139 ,  A61M2205/586

    摘要： The present invention relates to a holder for an injection syringe (18), with a housing (12) designed to receive the syringe, with a stand (14) for placing on a supporting surface, and with retaining means (38, 52, 54, 62, 64) for axially and/or radially fixing the syringe (18) on or in the holder, wherein the retaining means (38, 52, 54, 62, 64) are designed in such a way that an outlet (26) of a syringe (18) arranged vertically in the holder comes to lie facing the free end of the stand (14) and at a distance therefrom.

    摘要翻译： 本发明涉及一种用于注射器（18）的保持器，其具有设计成容纳注射器的壳体（12），其具有用于放置在支撑表面上的支架（14），以及具有保持装置（38,52,54 ，62,64），其用于在所述保持器上或所述保持器中轴向和/或径向固定所述注射器（18），其中所述保持装置（38,52,54,62,64）被设计成使得出口（26） 位于支架上垂直布置的注射器（18）面向支架（14）的自由端并与其距离一定距离。